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Background:  Since  protective  efﬁcacy  of the  current  typhoid  vaccines—oral  whole-cell  Salmonella  Typhi
Ty21a  and  parenteral  Vi-capsular  polysaccharide  preparation—is  not  optimal,  and  no vaccines  are avail-
able  against  paratyphoid  or non-typhoidal  Salmonella  (NTS)  serotypes,  new  approaches  deserve  to  be
explored.  The  immunological  mechanisms  elicited  by the  two  typhoid  vaccines  are  mainly  targeted
against  different  structures.  We  studied  whether  these  vaccines  would  enhance  S.  Typhi-speciﬁc  immune
response  and  cross-reactivity  against  other  Salmonellae,  if  administered  concomitantly.
Materials  and  methods:  Volunteers  were  immunized  simultaneously  with  Ty21a and  Vi  vaccines
(Ty21a  + Vi  group)  or with  either  of the  two  singly  (Ty21a  and  Vi  groups).  All volunteers  were  inves-
tigated  for circulating  speciﬁc  and  cross-reactive  plasmablasts,  identiﬁed  by ELISPOT  as  IgA,  IgG or  IgM
antibody-secreting  cells  (ASC)  reactive  with  S. Typhi,  S. Paratyphi  A/B/C,  or  selected  NTS  serotypes  (S.
Enteritidis,  S. Typhimurium).
Results: In  the Ty21a  +  Vi  group,  no speciﬁc  or cross-reactive  plasmablasts  were  detected  before  vac-
cination.  After  vaccination,  the number  of  S. Typhi-speciﬁc  plasmablasts  (878 ASC/106 PBMC,  95%CI
554–1201)  proved  higher  than  in the  Ty21a  (339  ASC/106 PBMC;  p <  0.001)  and  Vi  (149 ASC/106 PBMC;
p  <  0.001)  groups.  Likewise,  cross-reactive  responses  in  the  Ty21a  +  Vi group  were  higher  than  in the
Ty21a  and  Vi  groups  (Ty21a  +  Vi vs  Ty21a:  ASC  against  S. Paratyphi  A/B,  S.  Enteritidis  and  S.  Typhimurium
p  <  0.05,  against  S.  Paratyphi  C p  <  0.01;  Ty21a  + Vi  vs  Vi:  against  S. Paratyphi  C not signiﬁcant,  others
p  <  0.0001).  A gut-directed  homing  proﬁle  was  seen  among  O antigen-speciﬁc  and  a systemic  one  amongLISPOT
omingClinicalTrials.gov NCT02121145
Vi  antigen-speciﬁc  plasmablasts.
Conclusions:  Concomitant  administration  of  Ty21a  and  Vi  vaccines  is  well  tolerated  and  induces  an  addi-
tive  immune  response  to the two vaccines.  Thus  it enhances  the magnitude  of  both  typhoid-speciﬁc
plasmablast  responses  and  those  cross-reacting  with  paratyphoid  and most  important  NTS  serotypes.
The  data  encourage  concomita
©  2014  The  Authors.  Publis
Abbreviations: ASC, antibody-secreting cell; CLA, cutaneous lymphocyte antigen; 
almonella;  PBMC, peripheral blood mononuclear cell; PBS, phosphate-buffered saline.
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. Introduction
Diseases caused by Salmonella species constitute a serious
ealth problem worldwide. Salmonella enterica subspecies enter-
ca serotype Typhi (S. Typhi) causes typhoid fever, while S. enterica
ubspecies enterica serotype Paratyphi A/B/C (S. Paratyphi A/B/C)
re the etiological agents of paratyphoid fever. Together known
s enteric fever, typhoid and paratyphoid mostly prevail in devel-
ping countries, where they pose a health risk also to visitors.
on-typhoidal Salmonellae (NTS) cause food-borne gastroenteritis
nd invasive non-typhoidal salmonellosis (iNTS); they are encoun-
ered both in the developing and developed world. Globally, the
nnual incidence of typhoid fever is estimated at 22 million [1],
aratyphoid fever at 5.4 million [1], and NTS diseases at 94 million
ases [2]. Because of increasing antimicrobial resistance, the need
or preventive measures such as vaccination has become more and
ore urgent.
Currently, two types of vaccines—oral live attenuated Salmonella
yphi Ty21a (Vivotif®) and the parenteral capsular Vi polysaccha-
ide preparations (Typherix® or Typhim Vi®)—are available against
yphoid fever, while none are licensed against paratyphoid or NTS
erotypes. Interestingly, Ty21a and, to a lesser extent, the Vi vaccine
ave been shown to elicit cross-reactive immune responses against
aratyphoid serotypes [3–9] and the most common NTS Salmonel-
ae [10,11]. The main underlying cause of cross-reactivity are the
-antigenic structures these strains share with S. Typhi: while S.
yphi expresses O-9,12, S. Paratyphi A and B carry the O-12, and
any NTS Salmonellae express either O-9,12 (e.g. S. Enteritidis) or
-12 (e.g. S. Typhimurium). Speciﬁc and cross-reactive humoural
mmune responses can be explored at single-cell level with the help
f plasmablasts appearing transiently in the circulation after vac-
ination [5,10,16–18]. Indeed, plasmablasts are of special interest
hen studying typhoid vaccines: they have been suggested as sur-
ogate markers of protection against the disease [19]. Plasmablasts
epresent recently activated B cells trafﬁcking, via lymphatics and
lood, from the site of antigen encounter to their ﬁnal effector sites
20]. Before homing to tissues, these cells can be caught from the
irculation for a period of approximately one week, their magni-
ude peaking on day 7 [16,17]. The homing process is known to be
issue-speciﬁc: sc. homing receptors (HR) and chemokine receptors
CCR) on lymphocyte surface recognize their ligands in target tis-
ues [20]. Analysis of HR and CCR on circulating plasmablasts can be
sed to explore the expected localization of the immune response
21–25]. The cells are guided by the HR 47-integrin to the intes-
ine [26], l-selectin mainly to systemic sites [27], and cutaneous
ymphocyte antigen (CLA) to the skin [28].
Even if the two typhoid vaccines, Ty21a and Vi, have in ﬁeld trials
xhibited a similar protection rate of 60–70% against typhoid fever
29,30], their underlying protective mechanisms differ. Ty21a is a
ive Vi-negative whole-cell vaccine shown both to elicit humoral
19] and cell-mediated immune responses [19], while the Vi prepa-
ation consists of puriﬁed capsular Vi polysaccharide eliciting a
umoural response mainly to the Vi antigen [18,19]. We  hypothe-
ized that, given at the same time, the beneﬁts of both vaccines
ould be exploited. This is the ﬁrst study to explore immune
esponse to the two vaccines administered concomitantly.
. Materials and methods
.1. Study designThree groups were immunized: one receiving both Ty21a
nd Vi vaccines simultaneously (Ty21a + Vi group), the other two
ither Ty21a (Ty21a group) or Vi vaccine (Vi group). Circulat-
ng speciﬁc and cross-reactive plasmablasts were identiﬁed bye 33 (2015) 451–458
enzyme-linked immunospot assay (ELISPOT) as IgA, IgG and IgM
antibody-secreting cells (ASC) with given speciﬁcity. The plas-
mablasts’ homing potentials were characterized by combining
immunomagnetic cell sorting with the ELISPOT. Results of the
Ty21a and Vi groups have been reported earlier [9,11,18].
The study protocol was  approved by the ethics commit-
tee of the Helsinki University Central Hospital and the Finnish
Medicines Agency (EudraCT 2009-012949-33), and registered in
the databases required (ClinicalTrials.gov NCT02121145). Written
informed consent was obtained from all subjects. The investiga-
tion was conducted at the Travel clinic of the Medical Centre Aava,
Helsinki University Central Hospital and the Haartman Institute,
University of Helsinki.
2.2. Volunteers, vaccinations and samples
The Ty21a and Vi groups, each comprised 25 vaccinees, 17
females and 8 males, aged 22–62, mean age 32, as presented earlier
[9,11,18]. The Ty21a + Vi group included twenty-four Finnish-born
volunteers (11 females, 13 males, aged 22–29, mean 25 years) with
no history of enteric fever or typhoid vaccination. They received
both the oral Salmonella Typhi Ty21a vaccine (Vivotif®, Crucell AB,
Leiden, The Netherlands, lot 3000620) and the parenteral Vi capsu-
lar polysaccharide vaccine (Typherix®, GlaxoSmithKline Biologicals
s.a., Rixensart, Belgium, lot ATYPB096AF with endotoxin contents
of 13.30EU) at the same time. The oral vaccine, containing at least
2 × 109 live bacteria/capsule, was administered as one capsule on
days 0, 2, and 4, and the Vi vaccine as one 0.5 ml  dose intramuscu-
larly (25-mm needle) on day 0. Blood samples were drawn on days
0 and 7. The Ty21a and Vi groups were immunized 2010–2011 and
the Ty21a + Vi group 2013. The ELISPOT assay was validated before
the study, and proved to be highly repetitive (data not shown).
Combined use of the two  vaccines was  well tolerated: 7/24
vaccinees reported mild adverse effects (loose stools 2, one each:
stomachache, nausea, ﬂatulence, dizziness after injection, aphtha
in the mouth) resembling those seen in the Ty21a (stomachache
1, tiredness 1) and Vi (one each: fever, loose stools, pain at the
injection site, constipation) group.
2.3. Isolation of peripheral blood mononuclear cells (PBMC)
PBMC were separated using Ficoll-paque centrifugation of hep-
arinized venous blood, as described before [16].
2.4. Separation of HR-negative and -positive cell populations
Because of limited numbers of PBMC, HR analyses could not be
carried out for all volunteers. Four in the Ty21a + Vi group were
subjected to an analysis of HR expressions on O-9,12-speciﬁc ASC
and one volunteer to HR expressions on Vi antigen-speciﬁc ASC as
described earlier [10,18,22]. Brieﬂy, PBMCs (3.4 × 106 PBMC per HR)
were incubated with monoclonal antibodies against 47 (ACT-
1, Millennium Pharmaceuticals, Cambridge, MA), l-selectin (Leu
8, Becton Dickinson, Erenbodegem-Aalst, Belgium), or CLA (HECA-
452, a gift from Dr. Sirpa Jalkanen, Finland). Next, the cells were
incubated with Dynal® M-450 magnetic beads coated with sheep
anti-mouse IgG (Dynabeads, Dynal Biotech, Oslo), followed by mag-
netic separation and ELISPOT assay.
2.5. ELISPOT assay for speciﬁc and cross-reactive ASCPBMCs and, for HR analyses, the receptor-positive and -negative
cell populations, were assayed for ASC with ELISPOT as described
earlier [10,16]. In brief, 96-well microtitre plates (Maxisorp, Nunc,
Roskilde, Denmark) were coated with whole-cell bacteria (Table 1)
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Table  1
Description of bacterial strains and speciﬁc and cross-reactive plasmablast responses. Data are provided on bacterial strainsa used in the ELISPOT assay, the O and Vi antigens
of  each strain, proportion of responders, and numbers of antigen-speciﬁc ASC shown by volunteers in the Ty21a + Vi, Ty21a and Vi groups (arithmetic means of Ig(A + G + M)-
ASC  and 95% CI). Response to S. Typhi is calculated as the total of responses to the O-9,12 and Vi antigens. The data on the Ty21a or Vi groups have been retrieved from our
previous reports [9,11,18].
Bacterial
straina
Strain O antigens and Vi
antigen
Plasmablast response
% Responding Arithmetic mean (95%CI) ASC/106 PBMC
Ty21a + Vi Ty21a Vi Ty21a + Vi Ty21a Vi
S. Typhi Value calculated 9, 12, Vi 100 100b 100b 878 (554–1201) 339 (155–521)b 149 (81–217)b
S. Paratyphi A RHS6716 1, 2, 12 92 88c 60c 228 (117–339) 111 (31–197)c 20 (2–37)c
S. Paratyphi B RHS6744 1, 4, 5, 12 96 92c 72c 310 (149–471) 137 (39–236) c 22 (4–39)c
S. Paratyphi C ATCC 13428 6, 7, Vi 63 36c 64c 104 (21–187) 4 (1–6)c 22 (8–35)c
S. Enteritidis RHS634 1, 9, 12 100 100d 96d 555 (341–768) 364 (235–493)d 38 (19–55)d
S. Typhimurium 8965 1, 4, 5, 12 96 92d 76d 297 (153–442) 222 (105–339)d 22 (8–37)d
S. Hadar RHS148 6, 8 29 24d 8d 5 (1–9) 1 (1–2)d 1 (1–1)d
Yersinia enterocolitica RHI4823 – 8 0b 4b 1 (0–1) 0 (0–1)b 1 (1–2)b
a S. Paratyphi C strain was obtained from the American Type Culture Collection (ATCC, Manassas, VA), while the others were from the National Institute for Health and
Welfare, Helsinki, Finland.
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mb Data retrieved from our previous report [18].
c Data retrieved from our previous report [9].
d Data retrieved from our previous report [11].
r Vi antigen, as described earlier [5,10,18]. To conﬁrm the expres-
ion of the various O and Vi antigens on the coating strains,
ach strain had been analysed at the Finnish national refer-
nce laboratory (Gastroenterological Unit of the National Institute
or Health and Welfare in Helsinki) according to their routines.
ext, PBMCs were incubated in the wells, and the antibodies
ecreted were detected with alkaline phosphatase-conjugated goat
nti-human IgA (Sigma-Aldrich), IgG (Sigma-Aldrich) and IgM
SouthernBiotech, Birmingham, England). The substrate (5-bromo-
-chloro-3-indolyl phosphate p-toluidine salt; Sigma-Aldrich) was
dded in melted agarose. Each spot enumerated with an AID Elispot
eader or by microscope was interpreted as a print of one ASC. A
esponder was deﬁned as one having at least 3 ASC/106 PBMC; this
imit was marked as LOD (limit of detection of the response).
.6. Statistics
The proportions of the receptor-positive ASC were calculated
s follows: percentage of receptor-positive ASC = (100 × number of
SC in receptor-positive cell population)/the sum of the number of
SC in receptor-positive and -negative cell populations.
Statistical analyses were carried out with JMP software version
1.0.0 (SAS Institute Inc, Cary, NC, USA). The distributions of the
SC were veriﬁed with Shapiro–Wilk’s test. Since not all proved
ormal even after log transformations, Wilcoxon signed-rank test
as used for comparisons.
. Results
.1. S. Typhi-speciﬁc ASC responses
None of the vaccinees in the Ty21a + Vi group had circu-
ating S. Typhi-speciﬁc ASC before vaccination. On day 7, such
SC were found in all volunteers: 636 (95%CI 394–879) ASC
IgA + IgG + IgM)/106 PBMC as an arithmetic mean of O-9,12-
peciﬁc, and 250 (95%CI 52–449) Vi-speciﬁc ASC, totalling 878
95%CI 554–1201) S. Typhi-speciﬁc ASC (Fig. 1 and Table 1). The
espective ﬁgures for Ty1a and Vi groups have been reported earlier
18].
.2. Cross-reactive ASC responsesNone of the volunteers in the Ty21a + Vi group had circulating
SC cross-reactive with Salmonellae before vaccination. By day 7
ost vaccinees had developed plasmablasts cross-reactive withserotypes sharing O or Vi antigen(s) with S. Typhi: 22/24 showed
a response to S. Paratyphi A, 23/24 to S. Paratyphi B, 15/24 to S.
Paratyphi C, 24/24 to S. Enteritidis and 23/24 to S. Typhimurium
(Table 1 and Fig. 2). Minuscule amounts of plasmablasts against S.
Hadar (O-6,7) were found in the blood of 7/24 vaccinees, and of
2/24 vaccinees against Yersinia enterocolitica,  the negative control
strain (Table 1 and Fig. 2B). Results for the Ty1a and Vi groups have
been reported earlier [9,11]. In the Ty21a + Vi group, the responses
to strains sharing two O antigens (O-9,12; S. Enteritidis) with S.
Typhi proved higher than responses to strains sharing only one
O antigen (O-12; S. Typhimurium) as shown in Table 2. We  have
previously reported a respective difference in the Ty21a and Vi
groups [9,11]. As a rule, all those with a strong response to S. Typhi
also showed strong cross-reactive responses and vice versa—a log-
ical consequence in this study actually exploring the same cells for
speciﬁc and cross-reactive capacity. The proportions of responders
and arithmetic mean of typhoid-speciﬁc and cross-reactive ASC are
presented in Table 1.
3.3. Comparison of ASC responses between Ty21 + Vi, Ty21a and
Vi groups
The Ty21a + Vi group showed a higher S. Typhi-speciﬁc ASC
response than the other two  groups (Fig. 1). Likewise, the cross-
reactive responses to S. Paratyphi A and B (Fig. 2A), S. Enteritidis
and S. Typhimurium (Fig. 2B) proved stronger in the Ty21a + Vi
group than the others (Fig. 2B). The response to S. Paratyphi C
was found higher in the Ty21a + Vi than the Ty21a group (p < 0.01),
and equal to that in the Vi group (Fig. 2A). Compared to the
“gold standard”—the S. Typhi (total of O-9,12-and Vi)-speciﬁc ASC
response in the Ty21a group—the Ty21a + Vi group exhibited equal
cross-reactive response to S. Paratyphi A, B and to S. Typhimurium,
and higher to S. Enteritidis (Fig. 3).
3.4. Expression of ˛4ˇ7, l-selectin and CLA on O-9,12-speciﬁc ASC
In the Ty21a + Vi group, the O-9,12 antigen-speciﬁc ASC showed
a mucosal homing proﬁle: almost all of these cells expressed the
intestinal HR, 47-integrin, while the peripheral lymph node HR,
L-selectin, and the cutaneous HR, CLA were found less frequently.
At the same time, the Vi-speciﬁc ASC exhibited a systemic hom-
ing proﬁle: high proportion of L-selectin+ and lower proportion of
47+ or CLA+ cells (Fig. 4).
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Fig. 1. Typhoid-speciﬁc plasmablasts in volunteers immunized concomitantly with the Ty21a and Vi vaccine or with either of the two singly. Data are presented as numbers
of  circulating ASC (/106 PBMC) speciﬁc to O-9,12 or Vi antigen and as the total of these responses. Dots represent results of individual vaccinees and lines the medians of
I espon
c y21a a
s
4
i
t
n
e
t
b
t
a
s
s
h
o
l
M
a
i
t
e
T
C
t
ig(A  + G + M)-ASC on day 7 after vaccination. LOD = lower limit of detection of the r
alculated value. Results of statistical comparisons (Wilcoxon signed-rank test) to T
igniﬁcant. Data on the Ty21a and Vi groups have been published earlier [18].
. Discussion
The Ty21a and Vi vaccines are considered to exploit different
mmunological mechanisms when conferring protection against
yphoid fever. As neither of them has an optimal protection rate,
ew approaches deserve to be explored. This is the ﬁrst study to
xplore concomitant administration of the two vaccines. One of
he major ﬁndings was that the plasmablast responses appear to
e additive, suggesting that the two vaccines can well be given
ogether. An enhanced plasmablast response was found not only
gainst S. Typhi, but also against paratyphoid A and B strains, and
elected NTS serotypes, all sharing O antigens with S. Typhi.
The levels of S. Typhi-speciﬁc plasmablasts are of special interest
ince, in earlier studies, increasing numbers of plasmablasts [16]
ave been found to correlate with increasing protective efﬁcacy
f typhoid vaccines in ﬁeld trials [31,32]. Accordingly, plasmablast
evels have been suggested as surrogate markers of protection [19].
easuring plasmablasts at single-cell level offers a more sensitive
pproach to studying humoural immune response than determin-
ng serum antibodies [16,18,33].
In our plasmablast assay, whole bacteria were used for coating
o cover all possible surface antigens. As shown previously, how-
ver, the responses appear to be mainly targeted against the LPS
able 2
omparison of the responses to different pathogens in Ty21a + Vi group. The statistical com
he  responses to various strains. Signiﬁcant differences are indicated with asterisks (*** p <
s  calculated as the total of responses to the O-9,12 and Vi antigens.
Bacterial strain Comparison with plasmablast response to
S. Typhi S. Paratyphi A S. Paratyphi B 
S. Paratyphi A ***
S. Paratyphi B *** **
S. Paratyphi C *** NS **
S. Enteritidis *** *** ***
S. Typhimurium *** * NS
S. Hadar *** *** *** 
Yersinia enterocolitica *** *** ***se. No LOD values are given for the total response, since these ﬁgures represent a
nd Vi groups are provided: *** p < 0.001; ** 0.001 < p < 0.01; * 0.01 < p < 0.05; NS = not
structures, since the differences in them have proved to strictly
obey the expression of O antigens: a high response is seen to
any Salmonella strain with both typhoidal O antigens (O-9,12), a
moderate one to any strain with only one (O-12), and none/only
a negligible one to all those with no typhoidal O antigens. The
minuscule response to Salmonella Hadar (O-6,8) in this study was
presumably due to the presence of minor antigens shared, such
as some protein structures. A response proﬁle correlating with O
antigen expressions has been shown for both the Ty21a and the
Vi vaccine [9,11]. For the Ty21a, a whole cell vaccine carrying the
O-9,12 antigens, this is an expected ﬁnding, whereas for the Vi vac-
cine containing puriﬁed Vi capsular polysaccharide, the response
appears to consist of plasmablasts part of which are Vi-speciﬁc and
others targeted to the contaminating LPS [11,18]. In fact, in early
studies reporting serum antibodies to LPS in Vi vaccinees, the lev-
els have proved to correlate positively with the LPS content of the
preparation: 5% of LPS caused seroconversion in 83% of vaccinees,
and 0.2% of LPS in only 26% [34].
Concomitant administration of the two  vaccines brought about
an additive plasmablast response and thus an enhanced S. Typhi-
speciﬁc response. While Ty21a is known to induce a strong
O antigen-speciﬁc response and the Vi vaccine mostly a Vi-
speciﬁc one [18], the enhancement proved to be produced by the
parison (Bonferroni corrected Wilcoxon signed rank test) was carried out between
 0.001; ** 0.001 < p < 0.01; * 0.01 < p < 0.05). NS = not signiﬁcant. Response to S. Typhi
S. Paratyphi C S. Enteritidis S. Typhimurium S. Hadar
***
*** ***
* *** ***
*** *** *** NS
S.H. Pakkanen et al. / Vaccine 33 (2015) 451–458 455
Fig. 2. Cross-reactive plasmablast in volunteers immunized concomitantly with the Ty21a and Vi vaccines vs. either of the two  singly. Data are provided as the numbers of
circulating ASC (IgA + G + M)  cross-reactive with S. Paratyphi A/B and C in panel A and S. Enteritidis, S. Typhimurium, S. Hadar and the negative control Yersinia enterocolitica
in  panel B on day 7 after vaccination. LOD = lower limit of detection of the response. The short horizontal lines provide the medians of the responses. Results of statistical
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ith  one O antigen (O-12) and V indicates Vi antigen in common with S. Typhi. Dat
 antigen-speciﬁc response, for the Vi-speciﬁc one equalled that
n the Vi group. This result is logical: Ty21a does not express the
i antigen, nor does it contribute to the Vi-speciﬁc plasmablasts
n the Ty21a + Vi group, while the Vi vaccine contributes both a
i-speciﬁc and a low O-9,12-speciﬁc one [18]. The total S. Typhi-
peciﬁc response in the Ty21a + Vi group was thus by and large
he total of responses elicited by the two vaccines. Logically, the
nhanced immune response observed should indicate higher pro-
ective efﬁcacy, yet such a conclusion needs to be veriﬁed by ﬁeld
rials.Data on concomitant use of any vaccines is scarce. Simulta-
eous administration has in some cases been shown to decrease
he response to one of the individual preparations [35,36]. The
esponse in the Ty21a + Vi group approximately equalled the total < 0.001; ** 0.001 < p < 0.01; * 0.01 < p < 0.05; NS = not signiﬁcant. + indicates strains
e Ty21a and Vi groups have been published earlier [9,11].
of responses in the Ty21a and Vi groups, suggesting that these
vaccines not inﬂuence each other, but instead the responses be
additive, thus encouraging their concomitant use.
We have previously reported that the Ty21a and Vi vaccines
both elicit a cross-reactive response to S. Paratyphi A and B
[5,9], Ty21a one greater in magnitude [9]. The cross-reactivity
is attributed to the O-12 antigen shared between S. Typhi and
these paratyphoid strains. The magnitude of the cross-reactive
plasmablast response remains smaller than that to S. Typhi; accord-
ingly, in a ﬁeld trial in Chile, lower protective efﬁcacy has been
reported against S. Paratyphi B than against S. Typhi [37]. As
to S. Paratyphi A, several immunolocigal studies have shown
cross-reactivity [3–9], and two  have suggested some degree of
cross-protection [38,39]. The present study showed an enhanced
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Fig. 3. Cross-reactive plasmablast responses in group Ty21a + Vi in comparison to “gold standard”, S. Typhi-speciﬁc response elicited by Ty21a. Data are provided as numbers
of  circulating ASC speciﬁc to S. Typhi and cross-reactive to S. Paratyphi A and S. Paratyphi B, S. Enteritidis, S. Typhimurium in volunteers in the Ty21a + Vi group (grey bars), and
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u
ts  S. Typhi-speciﬁc ASC (total of O-9,12 and Vi-speciﬁc ASC) in the Ty21a group (bl
* 0.01 < p < 0.05), NS = not signiﬁcant. + Indicates strains with one O antigen (O-12) a
een  published earlier [18].
ross-reactive response in the Ty21a + Vi group against both S.
aratyphi A and B, suggesting that concomitant administration
f the two vaccines may  potentially enhance cross-protectivity
gainst S. Paratyphi A and B, yet ﬁeld trials are needed to conﬁrm
his. The signiﬁcance of the cross-reactive response to S. Paratyphi
 remains limited due to this pathogen’s rarity as cause of disease.
ig. 4. Homing potentials of circulating O-9,12- or Vi-speciﬁc plasmablasts in
y21a + Vi group. The bars indicate the arithmetic means + 95% CI of the proportions
f 47+, l-selectin+ or CLA+ plasmablast (IgA + IgG + IgM) reactive with O-9,12 or
i  antigen. The number of volunteers for whom the data were pooled are indicated
nder the bars. Statistical comparisons were not performed due to the scarcity of
ested volunteers.r). Statistical comparisons (Wilcoxon signed-rank test) are indicated with asterisk
two  O antigens (O-9 and O-12) in common with S. Typhi. Data on Ty21a group have
The lack of vaccines against NTS and iNTS diseases has directed
interest towards the cross-reactive potential of typhoid vaccines
[10,11]. In the Ty21a and Vi vaccines such mechanisms are linked
to O antigens shared between the NTS and S. Typhi strains.
Although the potential cross-protection has not been explored
in ﬁeld trials, numerous animal experiments attest to the sig-
niﬁcance of O antigen-speciﬁc antibodies for protection [40–44].
Studies with S. Typhimurium-infected mice have shown that both
systemic IgM and IgG and mucosal sIgA against O antigens pre-
vent lethal infections [41–43]; intestinal secretory IgA (sIgA) also
prevents local intestinal disease [42]. O antigen-speciﬁc sIgA pro-
motes agglutination and clearance by blocking bacterial binding
to epithelium receptors, capturing them in mucus, and assist-
ing their removal by peristaltic and mucociliary activities [40].
It also affects the functionality of Salmonella, rendering it tem-
porarily avirulent [45,46]. Serum IgG and IgM antibodies against
O antigen have been demonstrated to generate complement-
[43,47–49] and opsonization-mediated phagocytosis and killing of
Salmonella [3,44]. Furthermore, systemic O antigen-speciﬁc IgM
antibodies have proved more protective than the corresponding
IgG antibodies in mice [43]. Likewise, studies with humans sup-
port the protective role of O antigen-speciﬁc antibodies: serum
antibodies against O antigens have been suggested to serve a
protective function in antibody-induced complement-mediated
killing [48,49]; anti-Salmonella IgG and IgM antibody titres and
bactericidal activity of serum against NTS have been reported
to correlate negatively with number of NTS bacteraemia cases
[48].
In the present study the two most common serotypes, S. Enteri-
tidis and S. Typhimurium, were selected as representatives of NTS.
Consistent with the number of common O antigens, the response
to S. Enteritidis (O-9,12) has in our previous investigations proved
as high as the response to S. Typhi, while that to S. Typhimurium
(O-12) has been somewhat lower [10,11]. Now, after concomitant
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dministration of the two vaccines, the cross-reactive O antigen-
peciﬁc responses were found higher than in either of the groups
eceiving only one vaccine. Indeed, in the Ty21a + Vi group, the
agnitude of responses against strains with only one typhoid O
ntigen equalled the level of responses to strains with two  O anti-
ens in the Ty21a group. In the Ty21a + Vi group, the response to S.
yphi proved higher than that to S. Enteritidis, presumably because
f the Vi response, yet both exceeded the responses to strains with
nly one typhoidal O antigen.
In addition to serotypes investigated here, the typhoidal O anti-
ens are expressed by several other common NTS and iNTS types
12–15,50,51]. For example, S. Dublin, commonly isolated in iNTS in
frica [50] expresses both the typhoidal O antigens and the Vi anti-
en. S. Heidelberg, a serotype which has caused several outbreaks
n US recently [51], expresses O-12 antigen. Hence, the clinical sig-
iﬁcance of the potential cross-protection would presumably cover
ore strains than the two most common ones explored here.
The number of S. Typhi -speciﬁc plasmablasts has been shown to
orrelate with protective efﬁcacy against typhoid fever in ﬁeld trials
16,31,32]. Three doses of Ty21a vaccine in enteric-coated capsules
ave provided a protective efﬁcacy of 60–70% against S. Typhi in
eld trials [29,30]. Our study, using the same vaccination protocol in
he Ty21a group, showed a mean of 339 (155–521) S. Typhi-speciﬁc
lasmablasts/106 PBMC. If this response in the Ty21a group was
aken as the “gold standard” against which other responses were
ompared, the Ty21a + Vi group had a higher response to S. Typhi
nd S. Enteritidis, and an equal one to S. Paratyphi A, S. Paratyphi
, and S. Typhimurium. Whether this implies enhanced protection
gainst S. Typhi and S. Enteritidis, and equal protection against the
thers, needs to be explored in ﬁeld trials. Importantly, however,
hile typhoid fever and paratyphoid fever share similar patho-
enesis, NTS disease differs in this respect: instead of systemic
anifestation, it is generally restricted to the intestinal region. The
ossible correlations between protection and plasmablast levels
ay  also prove different.
The homing potential of plasmablasts in the Ty21a + Vi group
as found to depend on their antigen-speciﬁcity: O-9,12 antigen-
peciﬁc cells exhibited a mucosal and Vi-speciﬁc a systemic
oming proﬁle. This accords with earlier ﬁndings in the Ty21a
nd Vi groups [18] and the dogma that homing proﬁles of plas-
ablasts depend on the site of antigen encounter [21–25]. Most
-9,12-antigen-speciﬁc cells were elicited by the Ty21a vaccine
n the gut and had a homing proﬁle resembling that in the
y21a group [5,10,18,23]. All Vi-speciﬁc cells were induced by
he Vi vaccine and had a homing proﬁle identical to that in
he Vi group, consistent with the parenteral administration route
11,18]. These homing data accord with the discussion above, sug-
esting that concomitant administration of the two vaccines be
mmunologically additive, and allowing exploitation of the two
accines’ range of mechanisms. Evidently, strong response to all
elevant antigens in both mucosal and systemic compartments
f the immune system provides an optimal setting for protec-
ion.
. To conclude
Our study shows that concomitant administration of the Ty21a
nd Vi vaccines is well tolerated and brings about an additive plas-
ablast response indicating that these vaccines can indeed be given
ogether. An enhanced immune response is elicited not only to S.
yphi but also to paratyphoid and NTS serotypes. Despite the lack of
tudies exploring protective efﬁcacy, it appears reasonable to pre-
ume a relation between immune response and clinical efﬁcacy. As
ong as new vaccines against S. Typhi, S. Paratyphi and/or NTS are
[e 33 (2015) 451–458 457
not available, we  suggest that concomitant administration of Ty21a
and Vi vaccines be encouraged for those at signiﬁcant risk.
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